San Francisco, CA. December 21st 2017. PRC Clinical will be attending the 36th J.P. Morgan Healthcare Conference on January 8- 11, 2018 in San Francisco, CA. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the pharmaceutical industry.

PRC Clinical will discuss drug development programs with current and future drug developers and present its range of Clinical Trial Management services. “We are thrilled to have the J.P. Morgan conference so close to our headquarters” said Curtis Head, CEO at PRC Clinical. “This conference is a unique opportunity for drug developers to match innovation with funding, find the right drug development partners, and optimize their clinical programs.”

PRC Clinical will be celebrating its 15-year anniversary in 2018, renewing their strong commitment to supporting drug development and innovation. In particular, the company has helped sponsors develop pioneering treatments in regenerative medicine and neurology, among multiple other indications. In recent years, the CRO has also been increasingly engaged with the clinical trial community in California and beyond. Since 2015, PRC Clinical has been organizing a series of expert panel and networking events in the San Francisco, San Diego, and Boston biotech hubs. The CRO is also an active member and supporter of the ACRP. PRC Clinical is proud to be an active sponsor of the Association of Clinical Research Professionals (ACRP). The association supports clinical research professionals through membership, training and development, and certification. In 2016, PRC Clinical received the Annual Sponsor Award from the ACRP Northern California Chapter.

The annual J.P. Morgan Healthcare Conference brings together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. The hundreds of companies presenting run the gamut, from start-ups to those with more than $300 billion in market cap, and encompass the entire global healthcare landscape, including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.